ABN 16 165 160 841

ASX RELEASE **17 February 2021**

AMPLIA INITIATES MULTIPLE DOSE STUDY OF AMP945

Melbourne, Australia: Amplia Therapeutics Ltd (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce that, based on the positive profile seen to date, it has commenced the Multiple Ascending Dose (MAD) study in the Phase 1 clinical trial of its proprietary focal adhesion kinase (FAK) inhibitor AMP945.

Amplia's Phase 1 trial in healthy volunteers is designed to study the safety and tolerability profile of AMP945 as well as a number of pharmaceutical parameters in human subjects. A Single Ascending Dose (SAD) study of AMP945 was first initiated whereby subjects are closely monitored after being given a single dose of the drug. The SAD study is nearing completion and has not identified any safety or tolerability concerns associated with the administration of ascending single doses of AMP945. On the basis of the profile seen so far, Amplia has now commenced the Multiple Ascending Dose (MAD) study with the first subjects being dosed this week. In this stage of the Phase 1 trial, 3 cohorts of subjects will be exposed to different doses of AMP945 for a total of 7 days. Data from the SAD and MAD studies will help establish the appropriate doses of AMP945 to be evaluated in Phase 2 clinical trials in patients that are expected to commence at the end of 2021.

In addition to studying the safety and tolerability of AMP945, the Phase 1 clinical trial was designed to study the impact of food on the absorption of AMP945, determine the pharmacokinetics of the drug, and explore the ability of the drug to inhibit the FAK enzyme in the human body. The study looking at the impact of food on drug absorption was completed in January and data from this study is currently being analysed. Data to determine inhibition of FAK in the human body will be collected as part of the MAD studies.

"We are delighted that we have been able to advance AMP945 into our MAD study on the basis of the positive data seen so far in the SAD study." said John Lambert, CEO of Amplia. "AMP945 is a very specific inhibitor of the FAK enzyme and has very little off-target activity. The excellent safety profile that we have seen in our SAD study to date is consistent with data from our preceding non-clinical studies. We are very encouraged by the data that we have seen from the trial so far and look forward to reporting headline results from this Phase 1 clinical trial in Q2 2021."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information
Dr. John Lambert
CEO and Managing Director
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).